System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Epublish 91 citations

PubMed: 36864446 DOI: 10.1186/s12967-023-04017-6

Immunogenic cell death in cancer: concept and therapeutic implications.

J Transl Med 21(1):162

Authors: Lorenzo Galluzzi, Oliver Kepp, Erik Hett, Guido Kroemer, Francesco M Marincola

Affiliations

  • Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
  • Sandra and Edward Meyer Cancer Center, New York, NY, USA.
  • Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA.
  • Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.
  • Sonata Therapeutics, Boston, MA, USA.
  • Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Institut Universitaire de France, Sorbonne Université, Inserm U1138, Paris, France.
  • Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
  • Kite Pharma Inc, Santa Monica, CA, USA.

Abstract

Mammalian cells responding to specific perturbations of homeostasis can undergo a regulated variant of cell death that elicits adaptive immune responses. As immunogenic cell death (ICD) can only occur in a precise cellular and organismal context, it should be conceptually differentiated from instances of immunostimulation or inflammatory responses that do not mechanistically depend on cellular demise. Here, we critically discuss key conceptual and mechanistic aspects of ICD and its implications for cancer (immuno)therapy.

MeSH

Cells, Therapeutics, Neoplasms, Biomedical Research, Immunogenic Cell Death

Cited by